Autoimmune Hepatitis with Elevated Serum IgG4 Levels Have a High Prevalence of Cirrhosis at Diagnosis

Table 1

Comparison of baseline characteristics.

	A group (N = 41)	B group (N = 111)	value
Male n (%)	14 (34.15)	14 (12.61)	0.002
Age at onset (years)	56 ± 11.43	49.49 ± 13.04	0.005
Age at diagnosis (years)	57.32 ± 11.54	52.90 ± 12.64	0.052
Pretreatment IAIHG score	15 (13–18.5)	17 (13–19)	0.324
Simplified diagnostic criteria score^A	7 (6–8)	7 (6–8)	0.511
Cirrhosis n (%)	23 (56.10)	40 (36.04)	0.026
Platelet × 10^3/L (NR 100-300)	129 (88–168)	123 (85–186)	0.977
PT (NR 9.6–12.8)	13.3 (1235–16.65)	12.95 (11.80–14.50)	0.063
ALT (IU/L) (NR < 40)	110 (36–293)	114 (58–270)	0.544
AST (IU/L) (NR < 35)	128 (60–321)	134 (65–283)	0.692
TB (umol/L) (NR 5–28)	38.5 (20.25–91.05)	26.5 (17.3–66.4)	0.078
ALP (IU/L) (NR 50- 135)	149 (112–201)	134 (93–172)	0.056
GGT (IU/L) (NR < 45)	137 (61.5–222)	92 (43–173)	0.078
ALB (g/L) (NR 40–55)	34.4 (27.75–43.5)	38.6 (33.1–42.5)	0.028
GLB (g/L) (NR 20–40)	42.1 (34.05–47.75)	37 (31.1–43.7)	0.043
IgG (g/L) (NR 8–15.5)	24.8 (21.9–31.7)	20.9 (16.9–28.6)	0.016
IgM (mg/L) (NR 700–2200)	1400 (968.5–2005)	1775 (1220–2460)	0.013
IgG4 (g/L) (NR ≤ 1.35)	2.84 (1.82–3.5)	0.47 (0.262–0.837)	0.000
ANA positivity n (%)	27 (5.85)	86 (77.48)	0.145
Anti-LKM1 positivity n (%)	1 (2.44)	2 (1.82)	1.000
Anti-LC1 positivity n (%)	1 (2.44)	0 (0)	0.270
Anti-SLA/LP positivity n (%)	2 (4.88)	15 (13.51	0.227
p-ANCA positivity n (%)	1 (2.44)	12 (10.81)	0.190
EAD n (%)	4 (9.76)	30 (27.03)	0.023
Histology (severity of inflammation)^B	N = 39	N = 107	—
G1 n (%)	4 (10.26)	10 (9.35)	1.000
G2 n (%)	8 (20.51)	29 (27.10)	0.418
G3 n (%)	27 (69.23)	61 (57.01)	0.182
G4 n (%)	0 (0)	7 (6.54)	0.230
Fibrosis stages at diagnosis	N = 39	N = 107	—
S0 n (%)	1 (2.56)	4 (3.73)	1.000
S1 n (%)	7 (17.95)	28 (26.17)	0.303
S2 n (%)	6 (15.38)	32 (29.90)	0.077
S3 n (%)	11 (28.10)	23 (21.50)	0.396
S4 n (%)	14 (35.90)	20 (18.69)	0.030
Bile lesion n (%)	6 (15.38)	25 (23.36)	0.613
Remission^Cn (%)	23 (69.70%)	67 (76.14%)	0.470

PT, prothrombin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TB, total bilirubin; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; ALB, albumin; GLB, globulin; IgG, immunoglobulin G; IgM, immunoglobulin M; IgG4, immunoglobulin G4; ANA, anti-nuclear antibody; anti-LKM1, antibodies to liver kidney microsome type 1; anti-LC1, antibodies to liver cytosol type 1; anti-SLA/LP, antisoluble liver antigen/liver pancreas antibody; p-ANCA, perinuclear antineutrophil cytoplasmic antibody; and EAD, extrahepatic autoimmune diseases. A: simplified diagnostic scoring system of the IAIHG [12]. B: 6 patients who did not receive liver biopsies were excluded. The liver biopsy results of all patients had inflammation presentation; thus, there was no G0 grade for inflammation grade. C: there were 33 patients in group A and 88 patients in group B who received regular treatment with a course of treatment longer than 6 months.